Gideon S. Katz-Meyerowitz

Wollongong, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Randomized clinical trials of COVID-19 vaccines are not designed to study non-specific effects on rare mortality.

Randomized clinical trials of COVID-19 vaccines are not designed to study non-specific effects on rare mortality.

Journal: iScience

Published: July 23, 2026

Reply to Letter to the Editor 'Three Additional Considerations for Interpreting HbA1c in Frail Older Adults With Diabetes'.

Reply to Letter to the Editor 'Three Additional Considerations for Interpreting HbA1c in Frail Older Adults With Diabetes'.

Journal: Australasian journal on ageing

Published: July 02, 2026

Agreement between seroprevalence- and model-based estimates of COVID-19 burden.

Agreement between seroprevalence- and model-based estimates of COVID-19 burden.

Journal: Global health action

Published: June 09, 2026

Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.

Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.

Journal: Diabetes, obesity & metabolism

Published: May 18, 2026

Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.

Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.

Journal: American journal of therapeutics

Published: April 17, 2026

GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.

GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.

Journal: Cancer immunology, immunotherapy : CII

Published: April 14, 2026

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.

Journal: Diabetes, obesity & metabolism

Published: January 13, 2026

Follow-up investigation of ethics approvals and regulatory compliance in publications from the IHU-Mi.

Follow-up investigation of ethics approvals and regulatory compliance in publications from the IHU-Mi.

Journal: Research integrity and peer review

Published: December 30, 2025

Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.

Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.

Journal: Therapeutic advances in endocrinology and metabolism

Published: December 20, 2025

Research integrity within systematic reviews: investigating the prevalence of studies by authors with multiple retraction histories in Cochrane reviews.

Research integrity within systematic reviews: investigating the prevalence of studies by authors with multiple retraction histories in Cochrane reviews.

Journal: Research integrity and peer review

Published: December 09, 2025

From referral to reality: utilisation of Medicare-funded allied health services among people with newly diagnosed diabetes.

From referral to reality: utilisation of Medicare-funded allied health services among people with newly diagnosed diabetes.

Journal: Australian journal of primary health

Published: November 06, 2025

Wearables Integrated Technology to support healthy behaviours in general practice patients with type 2 diabetes (WEAR-IT): study protocol for a cluster randomised controlled trial.

Wearables Integrated Technology to support healthy behaviours in general practice patients with type 2 diabetes (WEAR-IT): study protocol for a cluster randomised controlled trial.

Journal: BMJ open

Published: October 23, 2025

Showing 1-12 of 70

Last Updated: 09/26/2026